Skip to main content
Alligator Bioscience logo

Alligator Bioscience — Investor Relations & Filings

Ticker · ATORX ISIN · SE0024173637 LEI · 549300E15VI0MB7LXV19 ST Manufacturing
Open in API
Filings indexed 612 across all filing types
Latest filing 2020-09-04 Regulatory Filings
Country SE Sweden
Listing ST ATORX

About Alligator Bioscience

https://alligatorbioscience.se/en/

Alligator Bioscience is a clinical-stage biotechnology company that develops tumor-directed immuno-oncology antibody drugs. The company's core strategy is to activate the patient's own immune system to fight cancer. It utilizes a proprietary technology platform for the discovery and development of novel antibody-based pharmaceuticals. The development pipeline features several drug candidates, including its lead asset mitazalimab, a CD40 agonist. The company specializes in creating therapeutics that are designed to be effective against various forms of cancer.

Recent filings

Filing Released Lang Actions
Alligator Bioscience presents positive biomarker data demonstrating proof of mechanism in mitazalimab clinical Phase I study
Regulatory Filings Classification · 1% confidence The document is a press release from Alligator Bioscience dated September 4, 2020, announcing positive biomarker data from a clinical Phase I study of their drug candidate mitazalimab, which is being presented at a scientific conference (PEGS Summit). It discusses clinical development plans (Phase II CTA submission planned for December 2020) and provides updates on the drug's mechanism of action and safety profile. This content is characteristic of an announcement detailing scientific progress, clinical trial updates, and future development steps, which is typically classified as an Investor Presentation (IP) if it were the presentation itself, or more generally, a type of corporate/investor news release. Since it is not a formal regulatory filing (like 10-K or IR), nor a transcript (CT), nor a formal earnings release (ER), and it focuses heavily on scientific data presentation and pipeline updates aimed at investors, the closest fit among the provided options that captures this type of detailed scientific/pipeline update is Investor Presentation (IP), although it is presented as a press release. Given the options, and the focus on presenting data and development strategy to the investment community, IP is the most appropriate classification for this type of detailed scientific update, rather than a general Regulatory Filing (RNS). It is not a formal Earnings Release (ER) as it focuses on R&D data, not period financial results.
2020-09-04 English
Alligator Bioscience presenterar positiva biomarkördata från klinisk fas I-studie som bekräftar mitazalimabs verkningsmekanism
Regulatory Filings Classification · 1% confidence The document is a press release from Alligator Bioscience dated September 4, 2020, announcing positive biomarker data from a Phase I clinical study for their drug candidate, mitazalimab. It details scientific findings, mentions presentation at a conference (PEGS Summit), and outlines next steps for clinical development (filing a CTA for a Phase II study). This content structure—announcing scientific/clinical progress and future plans via a press release format—is characteristic of an Earnings Release (ER) or a general Regulatory Filing (RNS). Since it is not a full financial report (10-K, IR) or a transcript (CT), and it is an announcement of results/progress rather than a formal regulatory filing like a DIRS or DVA, it fits best as an Earnings Release (ER) if it were tied to a reporting period, or more generally, a Regulatory Filing (RNS) if it's just a scientific update. Given the context of a biotech company announcing clinical data and next steps, this is a standard form of corporate communication. It is not a formal financial report, nor is it a proxy statement or management discussion. It is a specific announcement of scientific progress. Since 'ER' is defined as 'Initial announcement of quarterly/periodical financial results (key highlights only)', and this is a scientific/clinical highlight announcement, it leans towards a general regulatory announcement. However, many biotech clinical updates are classified under ER if they accompany or substitute for a quarterly update, or RNS if they are standalone. Given the specific nature of announcing clinical trial data and future trial plans, and lacking explicit quarterly financial figures, RNS (Regulatory Filings - general fallback) is the safest classification, although ER is plausible if this was released around a quarterly reporting date. I will classify it as RNS as it is primarily a scientific/clinical update announcement, not a financial results summary.
2020-09-04 Swedish
Alligator Bioscience: Encouraging interim safety data in ATOR-1017 clinical Phase I study
Earnings Release Classification · 1% confidence The document is a press release dated August 27, 2020, announcing 'interim safety data' from a clinical Phase I study for a drug candidate (ATOR-1017). It details safety findings, dose escalation approval, quotes from the CEO, and announces a public R&D update/webcast scheduled for later that day to discuss pipeline developments, including ATOR-1017. This structure—a brief announcement of new scientific/development progress coupled with an invitation to a presentation/call—is characteristic of an Earnings Release (ER) or a general Investor Presentation (IP) announcement, but since it is focused on clinical data updates and an R&D update event, it most closely aligns with an announcement of key financial/operational highlights, which often overlaps with ERs, or a specific update intended for investors. Given the focus on clinical trial progress and the announcement of a public R&D update event (which functions similarly to an earnings call presentation), the most fitting category is Earnings Release (ER) as it conveys the period's key operational/scientific results, or Investor Presentation (IP) if the primary purpose was the presentation itself. However, the text is a formal press release announcing specific data points and an upcoming event. Since it is not a full transcript (CT) or a comprehensive quarterly report (IR), and it conveys key operational news, ER is a strong candidate. Alternatively, because it is announcing an R&D update event where presentations will be given, it could be seen as related to an Investor Presentation (IP). Given the context of clinical data release, which is a major operational update, ER is often used for these initial announcements. However, the document explicitly mentions an R&D update where presentations will be given, making IP also plausible. Since the document itself is the announcement of the data and the event, and not the presentation slides, I will classify it as an Earnings Release (ER) as it conveys the period's key operational results, or potentially RNS if it were too generic. Since it contains specific, time-sensitive operational data (safety profile, dose escalation), ER is better than RNS. It is not a full report (10-K/IR). I will lean towards ER as the primary announcement of period results/updates. FY 2020
2020-08-27 English
Alligator Bioscience: Lovande säkerhetsdata i klinisk fas I-studie med ATOR-1017
Regulatory Filings Classification · 1% confidence The document is a press release from Alligator Bioscience dated August 27, 2020, announcing positive safety data from a Phase I clinical trial for their drug candidate ATOR-1017. It details the observed side effects, the approval to proceed to a higher dose level, and includes quotes from management. Crucially, it announces a public R&D update/presentation scheduled for later that day where this data will be discussed. The text is a formal announcement of clinical progress and an invitation/agenda for a presentation, not the full presentation itself (IP) or a transcript (CT). Since it is a formal announcement of clinical trial progress and an update on development steps, it fits best under 'Regulatory Filings' (RNS) as a general corporate/clinical update that doesn't fit the more specific categories like ER, IR, or AR. Given the context of clinical trial updates, it is a specific type of regulatory disclosure, but RNS serves as the best general regulatory announcement category here, as it is not a formal financial report (10-K, IR, ER) or a presentation (IP). The document length (4462 chars) is substantial enough to be a full release, not just a brief RPA.
2020-08-27 Swedish
Alligator Bioscience presents the clinical project portfolio at Virtual R&D Day August 27, 2020
Investor Presentation Classification · 1% confidence The document is titled 'Alligator Bioscience presents the clinical project portfolio at Virtual R&D Day August 27, 2020' and provides detailed updates on the status, next steps, and clinical trial plans for several drug candidates (Mitazalimab, ATOR-1015, ATOR-1017). This content is characteristic of an Investor Presentation (IP) or a detailed update aimed at investors regarding pipeline progress, rather than a formal regulatory filing (like 10-K or IR) or a brief earnings release (ER). It is not a Call Transcript (CT) as it lacks Q&A structure, nor is it a simple announcement of a report (RPA/RNS). It is a substantive presentation of company strategy and development progress.
2020-08-25 English
Alligator Bioscience presenterar den kliniska projektportföljen vid virtuell FoU-dag den 27 augusti 2020
Regulatory Filings Classification · 1% confidence The document is a press release dated August 25, 2020, announcing that Alligator Bioscience will present updates on its clinical pipeline (mitazalimab, ATOR-1015, ATOR-1017) at a virtual R&D Day on August 27, 2020. It details the status, next steps (CTA submission, Phase I/Ib/II plans), and safety/efficacy signals for these drug candidates. The text concludes with a statement that a more detailed invitation will follow shortly and includes a boilerplate disclosure about market abuse regulation compliance. This structure—an announcement about upcoming detailed information/presentation, rather than the presentation itself or a comprehensive financial report—strongly suggests it is an announcement regarding future investor/research communication. Since it is an announcement about presenting R&D pipeline updates, it is most closely related to Investor Presentation (IP) material, but because the document itself is an announcement *about* the presentation, and not the presentation content itself, it fits best under the general category for regulatory announcements that precede specific events or filings, or potentially a general Investor Relations communication. Given the options, and the fact that it is a brief announcement detailing pipeline progress ahead of a specific event (R&D Day), it is not a full ER, IR, or 10-K. It is an announcement of company progress, which often falls under general regulatory filings (RNS) or, if it were the presentation itself, IP. Since it is a short announcement *about* an upcoming presentation, and not the presentation itself, RNS (Regulatory Filings) is the most appropriate fallback for this type of corporate news release that doesn't fit the specific financial report codes.
2020-08-25 Swedish

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.